Bluejay Diagnostics (BJDX) links director’s 100K options to FDA clearance
Rhea-AI Filing Summary
Bluejay Diagnostics, Inc. (BJDX) reported that director Svetlana Dey received a grant of 100,000 stock options to purchase common stock at an exercise price of $2.075 per share. The options vest and become exercisable on the first anniversary of the grant, but cannot be exercised unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device. These options expire on August 17, 2031, and following this grant Dey holds 100,000 options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Dey Svetlana
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 100,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 100,000 shares (Direct)
Footnotes (1)
- F1. Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.
Key Figures
Options Granted: 100,000 options
Exercise Price: $2.075 per share
Underlying Shares: 100,000 shares
+2 more
5 metrics
Options Granted
100,000 options
Stock Option (Right to Buy) grant to director Svetlana Dey
Exercise Price
$2.075 per share
Conversion or exercise price for the granted stock options
Underlying Shares
100,000 shares
Common Stock underlying the granted stock options
Expiration Date
August 17, 2031
Expiration of the granted stock options
Total Options After Grant
100,000 options
Total options held directly by Dey following the transaction
Key Terms
out-of-the-money stock options, point-of-care testing device, U.S. Food and Drug Administration, vest and become exercisable
4 terms
out-of-the-money stock options financial
"Represents out-of-the-money stock options that vest and become exercisable"
point-of-care testing device medical
"approval of the issuer's Symphony IL-6 point-of-care testing device"
U.S. Food and Drug Administration regulatory
"unless and until the U.S. Food and Drug Administration shall have granted clearance"
The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.
vest and become exercisable financial
"stock options that vest and become exercisable for $2.075 per share"
FAQ
What did BJDX disclose about insider Svetlana Dey in this Form 4?
BJDX disclosed that director Svetlana Dey received a grant of 100,000 stock options with an exercise price of $2.075 per share, vesting after one year and expiring on August 17, 2031.
What are the vesting terms of the 100,000 BJDX stock options granted to Svetlana Dey?
The 100,000 BJDX stock options granted to Dey vest and become exercisable on the first anniversary of the grant date. However, exercise is also conditioned on FDA clearance or approval of the Symphony IL-6 device.
What is the exercise price of the stock options granted to the BJDX director?
The stock options granted to the BJDX director have an exercise price of $2.075 per share. They are described as out-of-the-money options and relate to 100,000 shares of Bluejay Diagnostics common stock.
Are the BJDX stock options granted to Svetlana Dey immediately exercisable?
No. The options are not immediately exercisable; they vest after one year and are additionally conditioned so they shall not be exercisable until the FDA grants clearance or approval of the Symphony IL-6 point-of-care testing device.
How many BJDX options does Svetlana Dey hold after this reported transaction?
After the reported transaction, Svetlana Dey holds 100,000 stock options directly. These options relate to BJDX common stock, carry a $2.075 exercise price, and expire on August 17, 2031, subject to vesting and FDA-related conditions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
